Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine

Published:2017-05-25 Issue:1 Volume:14 Page:1141-1146
ISSN:1792-1074
Container-title:Oncology Letters
language:en
Short-container-title:

Author:

Wenger Katharina J.,Wagner Marlies,You Se-Jong,Franz Kea,Harter Patrick N.,Burger Michael C.,Voss Martin,Ronellenfitsch Michael W.,Fokas Emmanouil,Steinbach Joachim P.,Bähr Oliver

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the tumour vasculature: from vessel destruction to promotion;Nature Reviews Cancer;2024-08-29

2. Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond O-6-Methylguanine-DNA Methyltransferase;CNS & Neurological Disorders - Drug Targets;2023-07

3. Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors;Scientific Reports;2023-06-09

4. Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma;Frontiers in Neurology;2023-05-25

5. Recognition and Management of the Long-term Effects of Cranial Radiation;Current Treatment Options in Oncology;2023-05-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP